Product Description
Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation
Mechanisms of Action: Phosphatidylserine Binder
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alavita
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Kidney Transplant
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00615966 |
DAV-CL002 | P2 |
Completed |
Kidney Transplant |
2009-01-01 |
2019-03-18 |
Treatments |
|
NCT01442337 |
8597-CL-0201 | P3 |
Terminated |
Kidney Transplant |
2013-07-01 |
2019-03-19 |
Treatments |